Phylogenetic inference reveals clonal heterogeneity in circulating tumour cell clusters
Mechanical Conditioning (MeCo) Score Progressively Increases Through the Metastatic Cascade in Breast Cancer via Circulating Tumour Cells
Analytical validation of ANGLE’s combined IF and FISH assay for assessment of HER2 in circulating tumor cells
DDRi Summit 2025: Monitoring of DNA Damage Response Biomarkers using Circulating Tumour Cells captured with ANGLE’s Parsortix® instrument from Ovarian, Prostate, and Breast cancer patients
Digoxin for reduction of circulating tumour cell cluster size in metastatic breast cancer
SABCS: A novel, semi-automated Pipeline for HER2 Quantification on CTCs in breast cancer patients. Is cytopathology of peripheral blood a new diagnostic option?
AACR LBx 24 – Development of a scoring system to classify HER2 protein expression in Circulating Tumour Cells through immunofluorescence following isolation using Parsortix® instruments
DDR Conference – Detection of DNA Damage Response Biomarkers in Circulating Tumour Cells using ANGLE’s Parsortix® instrument and downstream immunofluorescence assays
Low‑pass whole genome sequencing of circulating tumor cells to evaluate chromosomal instability in triple‑negative breast cancer
Identification of circulating tumor cells captured by the FDA-cleared Parsortix® PC1 system from the peripheral blood of metastatic breast cancer patients using immunofluorescence and cytopathological evaluations